AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

October 31, 2008

Conditions
Pancreatic Cancer
Interventions
DRUG

AZD6244

oral capsule

DRUG

capecitabine

oral tablet

Trial Locations (17)

Unknown

Research Site, Alhambra

Research Site, Bakersfield

Research Site, Palm Springs

Research Site, Santa Maria

Research Site, Orlando

Research Site, Chevy Chase

Research Site, Ann Arbor

Research Site, New York

Research Site, Nashville

Research Site, Temple

Research Site, Seattle

Research Site, Heidelburg

Research Site, Plovdiv

Research Site, Sofia

Research Site, Varna

Research Site, Budapest

Research Site, Cluj-Napoca

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY